MMP9 Antibody

Code CSB-PA058909
Size US$297
Order now
Image
  • Western blot analysis of extracts from Hela cells using MMP-9 Antibody.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) MMP9 Polyclonal antibody
Uniprot No.
Target Names
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Peptide sequence around aa.110-114(F-E-G-D-L) derived from Human MMP-9.
Immunogen Species
Homo sapiens (Human)
Clonality
Polyclonal
Concentration
It differs from different batches. Please contact us to confirm it.
Tested Applications
ELISA,WB
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:1000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Usage
For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Customer Reviews and Q&A

 Customer Reviews
Average Rating:
5.0 - 1 reviews

Submit a Review here

Applications : Immunoblotting

Sample type: cells

Review: the protein levels were confirmed by Immunoblotting. Opposite to ID2 overexpression effects, the 740Y-P treatment decreased the protein levels of epithelial marker cadherin and increased N-cadherin, MMP2, and MMP9.

By Anonymous

CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2025 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*